Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic enzyme dose escalation vs acid suppression in exocrine pancreatic insufficiency
2015-002570-20Phase 4Active
- Sponsor
- Complejo Hospitalario Universitario de Santiago
- Start
- Apr 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pancreatin in exocrine pancreatic insufficiency (EPI) and chronic pancreatitis (CP) (4 arms), sponsored by Complejo Hospitalario Universitario de Santiago. Primary endpoint: Absolute increase in fat digestion with each treatment. Started Apr 2016; status: active.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)chronic pancreatitis (CP)
Beyond the preview
Go deeper on 2015-002570-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002570-20.